These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 29336814)

  • 1. Inhibition of Interleukin-10 in the tumor microenvironment can restore mesothelin chimeric antigen receptor T cell activity in pancreatic cancer in vitro.
    Batchu RB; Gruzdyn OV; Mahmud EM; Chukr F; Dachepalli R; Manmari SK; Mostafa G; Weaver DW; Gruber SA
    Surgery; 2018 Mar; 163(3):627-632. PubMed ID: 29336814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engraftment of mesothelin chimeric antigen receptor using a hybrid Sleeping Beauty/minicircle vector into NK-92MI cells for treatment of pancreatic cancer.
    Batchu RB; Gruzdyn OV; Tavva PS; Kolli BK; Dachepalli R; Weaver DW; Gruber SA
    Surgery; 2019 Oct; 166(4):503-508. PubMed ID: 31416604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesothelin-targeting chimeric antigen receptor-modified T cells by piggyBac transposon system suppress the growth of bile duct carcinoma.
    Xu JY; Ye ZL; Jiang DQ; He JC; Ding YM; Li LF; Lv SQ; Wang Y; Jin HJ; Qian QJ
    Tumour Biol; 2017 Apr; 39(4):1010428317695949. PubMed ID: 28381173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activated iNKT cells enhance the anti-tumor effect of antigen specific CD8 T cells on mesothelin-expressing salivary gland cancer.
    Makita Y; Kunii N; Sakurai D; Ihara F; Motohashi S; Suzuki A; Nakayama T; Okamoto Y
    BMC Cancer; 2018 Dec; 18(1):1254. PubMed ID: 30558663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy.
    O'Hara M; Stashwick C; Haas AR; Tanyi JL
    Immunotherapy; 2016; 8(4):449-60. PubMed ID: 26973126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer.
    Lv J; Zhao R; Wu D; Zheng D; Wu Z; Shi J; Wei X; Wu Q; Long Y; Lin S; Wang S; Wang Z; Li Y; Chen Y; He Q; Chen S; Yao H; Liu Z; Tang Z; Yao Y; Pei D; Liu P; Zhang X; Zhang Z; Cui S; Chen R; Li P
    J Hematol Oncol; 2019 Feb; 12(1):18. PubMed ID: 30777106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial.
    Beatty GL; O'Hara MH; Lacey SF; Torigian DA; Nazimuddin F; Chen F; Kulikovskaya IM; Soulen MC; McGarvey M; Nelson AM; Gladney WL; Levine BL; Melenhorst JJ; Plesa G; June CH
    Gastroenterology; 2018 Jul; 155(1):29-32. PubMed ID: 29567081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesothelin, a novel immunotherapy target for triple negative breast cancer.
    Tchou J; Wang LC; Selven B; Zhang H; Conejo-Garcia J; Borghaei H; Kalos M; Vondeheide RH; Albelda SM; June CH; Zhang PJ
    Breast Cancer Res Treat; 2012 Jun; 133(2):799-804. PubMed ID: 22418702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesothelin CAR-T cells secreting PD-L1 blocking scFv for pancreatic cancer treatment.
    Wang Y; Fang X; Li M; Ye J; Zhao S; Yu L; Wang J; Wang Y; Yan Z
    Cancer Genet; 2022 Nov; 268-269():103-110. PubMed ID: 36288641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineered CAR T cells targeting mesothelin by piggyBac transposon system for the treatment of pancreatic cancer.
    He J; Zhang Z; Lv S; Liu X; Cui L; Jiang D; Zhang Q; Li L; Qin W; Jin H; Qian Q
    Cell Immunol; 2018 Jul; 329():31-40. PubMed ID: 29859625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic cells adenovirally-transduced with full-length mesothelin cDNA elicit mesothelin-specific cytotoxicity against pancreatic cancer cell lines in vitro.
    Miyazawa M; Iwahashi M; Ojima T; Katsuda M; Nakamura M; Nakamori M; Ueda K; Naka T; Hayata K; Iida T; Yamaue H
    Cancer Lett; 2011 Jun; 305(1):32-9. PubMed ID: 21397388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of novel human CTL epitopes and their agonist epitopes of mesothelin.
    Yokokawa J; Palena C; Arlen P; Hassan R; Ho M; Pastan I; Schlom J; Tsang KY
    Clin Cancer Res; 2005 Sep; 11(17):6342-51. PubMed ID: 16144939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lyophilized lymph nodes for improved delivery of chimeric antigen receptor T cells.
    Shi J; Wu W; Chen D; Liao Z; Sheng T; Wang Y; Yao Y; Wu Q; Liu F; Zhou R; Zhu C; Shen X; Mao Z; Ding Y; Wang W; Dotti G; Sun J; Liang X; Fang W; Zhao P; Li H; Gu Z
    Nat Mater; 2024 Jun; 23(6):844-853. PubMed ID: 38448658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.
    Drent E; Groen RW; Noort WA; Themeli M; Lammerts van Bueren JJ; Parren PW; Kuball J; Sebestyen Z; Yuan H; de Bruijn J; van de Donk NW; Martens AC; Lokhorst HM; Mutis T
    Haematologica; 2016 May; 101(5):616-25. PubMed ID: 26858358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Possible Compartmental Cytokine Release Syndrome in a Patient With Recurrent Ovarian Cancer After Treatment With Mesothelin-targeted CAR-T Cells.
    Tanyi JL; Stashwick C; Plesa G; Morgan MA; Porter D; Maus MV; June CH
    J Immunother; 2017 Apr; 40(3):104-107. PubMed ID: 28234665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming barriers of car T-cell therapy in patients with mesothelin-expressing cancers.
    O'Hara MH; Stashwick C; Plesa G; Tanyi JL
    Immunotherapy; 2017 Aug; 9(9):767-780. PubMed ID: 28771103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesothelin-specific Immune Responses Predict Survival of Patients With Brain Metastasis.
    Zhenjiang L; Rao M; Luo X; Sandberg E; Bartek J; Schoutrop E; von Landenberg A; Meng Q; Valentini D; Poiret T; Sinclair G; Peredo IH; Dodoo E; Maeurer M
    EBioMedicine; 2017 Sep; 23():20-24. PubMed ID: 28888924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review.
    Nichetti F; Marra A; Corti F; Guidi A; Raimondi A; Prinzi N; de Braud F; Pusceddu S
    Target Oncol; 2018 Jun; 13(3):333-351. PubMed ID: 29656320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mesothelin-specific cell-based vaccine generates antigen-specific immunity and potent antitumor effects by combining with IL-12 immunomodulator.
    Chang MC; Chen YL; Chiang YC; Chen TC; Tang YC; Chen CA; Sun WZ; Cheng WF
    Gene Ther; 2016 Jan; 23(1):38-49. PubMed ID: 26262583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.